Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00038831 · ClinicalTrials.gov registry record · Phase 1
Allo Transplantation With Mylotarg, Fludarabine and Melphalan for AML, CML and MDS
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 47
- Enrollment target
NCT00038831: Completed Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT00038831 is a Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 47 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00038831, a Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 47 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to find the highest safe dose of Mylotarg that can be combined with chemotherapy in patients receiving allogeneic bone marrow transplantation. Researchers will study the effects of this treatment combination on patients with high-risk acute leukemia, chronic myelogenous leukemia, or myelodysplastic syndrome. Primary Objective: 1\. To determine the safety and maximum tolerated dose of Mylotarg as part of a reduced-intensity preparative regimen patients undergoing related, mismatched-related or matched unrelated donor transplantation. Secondary Objectives: 1. To evaluate response rates, engraftment kinetics and degree of chimerism achievable with this strategy. 2. To evaluate the incidence and severity of GVHD in this population 3. To evaluate disease-free and overall survival and relapse rates.
Interventions
- DRUG Fludarabine
- DRUG Melphalan
- DRUG Anti-thymocyte globulin
- PROCEDURE Stem cell transplant
- DRUG Mylotarg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2001-05 |
| Est. Completion | 2006-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00038831
The ClinicalTrials.gov registry entry for NCT00038831 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Fludarabine is the first listed.
NCT00038831 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00038831 about?
NCT00038831 is a clinical study titled "Allo Transplantation With Mylotarg, Fludarabine and Melphalan for AML, CML and MDS". The goal of this clinical research study is to find the highest safe dose of Mylotarg that can be combined with chemotherapy in patients receiving allogeneic bone marrow transplantation. Researchers will study the effects of this treatment combination on patients with high-risk acute leukemia, chron...
What is the current status of trial NCT00038831?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 47 participants. The study started on 2001-05. Estimated completion is 2006-10.
What interventions are being tested in trial NCT00038831?
The interventions under investigation include: Fludarabine (DRUG), Melphalan (DRUG), Anti-thymocyte globulin (DRUG), Stem cell transplant (PROCEDURE), Mylotarg (DRUG).
Who is sponsoring clinical trial NCT00038831?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.